biodexa-logo-square (1).png
Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024
July 02, 2024 08:30 ET | Biodexa Pharmaceuticals PLC
July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 After Only Two Infusions and Two...
Construction Underway: Solar Array at Croton Harmon Train Station
Columbia University Pledges Support of Solar Energy Project through Sol Systems in Croton-on-Hudson
January 30, 2024 07:00 ET | Sol Systems
Washington, D.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Today, Sol Systems, a leading renewable energy company, announced a clean energy project for which Columbia University will act as anchor tenant....
SILO_LOGO_A.png
Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease
October 27, 2021 08:15 ET | SILO PHARMA INC.
Englewood Cliffs, NJ, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
STUDY: PLUNGE IN EMI
STUDY: PLUNGE IN EMISSIONS DURING SHUTDOWN DEMONSTRATES POTENTIAL FOR HUGE ENVIRONMENTAL, HEALTH, AND ECONOMIC GAINS
December 21, 2020 14:41 ET | Abt Associates
Rockville, Md., Dec. 21, 2020 (GLOBE NEWSWIRE) -- A new study from Columbia University, Abt Associates, and ZevRoss Spatial Analysis finds that New York City’s two-month shutdown during...
Sakıp Sabancı International Research Awards Jury Prize Was Given to Prof. Joseph S. Nye, Jr.
April 22, 2019 09:30 ET | Sabancı University
Istanbul, April 22, 2019 (GLOBE NEWSWIRE) -- In honor of the late Sakıp Sabancı (1933-2004), a philanthropist and businessman who transformed family business into one of the largest conglomerates in...
BioDelivery Sciences logo
BioDelivery Sciences to Report Third Quarter 2018 Financial Results on November 8, 2018
October 23, 2018 08:00 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences logo
BioDelivery Sciences to Host Institutional Investor and Analyst Day on Friday, October 5, 2018
September 13, 2018 07:30 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 13, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences logo
BioDelivery Sciences to Present at the 2018 Janney Montgomery Scott Healthcare Conference
September 10, 2018 08:00 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 10, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial stage specialty pharmaceutical company dedicated to patients living...
BioDelivery Sciences logo
BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
August 21, 2018 08:00 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 21, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences logo
BioDelivery Sciences to Report Second-Quarter 2018 Financial Results on August 9, 2018
July 24, 2018 16:30 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 24, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it will report its second quarter 2018 financial results after the close...